blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2935332

EP2935332 - ANTI-H7CR ANTIBODIES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  16.09.2022
Database last updated on 11.04.2026
FormerThe patent has been granted
Status updated on  08.10.2021
FormerGrant of patent is intended
Status updated on  25.05.2021
FormerExamination is in progress
Status updated on  06.01.2017
Most recent event   Tooltip19.12.2025Lapse of the patent in a contracting state
New state(s): TR		published on 21.01.2026  [2026/04]
Applicant(s)For all designated states
MedImmune, LLC
One MedImmune Way
Gaithersburg, MD 20878 / US
For all designated states
The John Hopkins University
3400 N. Charles Street
Baltimore, MD 21218 / US
[2016/08]
Former [2015/50]For all designated states
MedImmune, LLC
One MedImmune Way
Gaithersburg, MD 20878 / US
For all designated states
The John Hopkins University
3400 N. Charles Street
Baltimore, MD 21218-2695 / US
Former [2015/45]For all designated states
Medimmune, LLC
One Medimmune Way
Gaithersburg, Maryland 20878 / US
For all designated states
The John Hopkins University
3400 N. Charles Street
Baltimore, MD 21218-2695 / US
Former [2015/44]For all designated states
Amplimmune, Inc.
45 West Watkins Mill Road
Gaithersburg, MD 20878 / US
For all designated states
The John Hopkins University
3400 N. Charles Street
Baltimore, MD 21218-2695 / US
Inventor(s)01 / LANGERMANN, Solomon
6606 Cross Country Boulevard
Baltimore, MD 21215 / US
02 / LIU, Linda
6512 Tipperary Court
Clarksville, MD 21029 / US
03 / YAO, Sheng
11748 Bryce Overlook Court
Columbia, MD 21004 / US
04 / CHEN, Lieping
51 Canterbury Road
Hamden, CT 06514 / US
 [2015/44]
Representative(s)Roth, Andy Stefan
Dr. Roth Patentanwaltskanzlei
Kaistrasse 5
40221 Düsseldorf / DE
[2021/45]
Former [2015/44]Roth, Andy Stefan
Dr. Roth Patentanwaltskanzlei
Columbusstrasse 22
40549 Düsseldorf / DE
Application number, filing date13822053.823.12.2013
[2015/44]
WO2013US77586
Priority number, dateUS201261745296P21.12.2012         Original published format: US 201261745296 P
US201261745312P21.12.2012         Original published format: US 201261745312 P
US201361827279P24.05.2013         Original published format: US 201361827279 P
US201361827269P24.05.2013         Original published format: US 201361827269 P
[2015/44]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014100823
Date:26.06.2014
Language:EN
[2014/26]
Type: A1 Application with search report 
No.:EP2935332
Date:28.10.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 26.06.2014 takes the place of the publication of the European patent application.
[2015/44]
Type: B1 Patent specification 
No.:EP2935332
Date:10.11.2021
Language:EN
[2021/45]
Search report(s)International search report - published on:EP26.06.2014
ClassificationIPC:A61P31/00, A61P31/12, A61P35/00, A61P37/02, A61P37/04, A61P43/00, C07K16/28, C12N15/10
[2020/28]
CPC:
C07K16/2818 (EP,RU,US); A61K39/39541 (US); A61K39/39533 (RU);
A61P31/00 (EP); A61P31/12 (EP); A61P35/00 (EP);
A61P37/02 (EP); A61P37/04 (EP); A61P43/00 (EP);
C07K16/2827 (EP,RU,US); C12N15/1037 (EP,RU,US); G01N33/505 (US);
G01N33/5759 (RU,US); G01N33/577 (US); C07K2317/24 (EP,US);
C07K2317/31 (US); C07K2317/33 (EP,US); C07K2317/56 (US);
C07K2317/565 (US); C07K2317/74 (EP,US); C07K2317/75 (US);
C07K2317/76 (EP,US); C07K2317/92 (EP,US); C07K2319/30 (EP,US);
G01N2333/70521 (US) (-)
Former IPC [2017/24]C12N15/10, G01N33/574, C07K16/28
Former IPC [2015/44]C07K16/28
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/44]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ANTI-H7CR ANTIKÖRPERN[2017/24]
English:ANTI-H7CR ANTIBODIES[2015/44]
French:ANTICORPS ANTI-H7CR[2015/44]
Former [2015/44]ANTI-H7CR-ANTIKÖRPER
Entry into regional phase16.07.2015National basic fee paid 
16.07.2015Designation fee(s) paid 
16.07.2015Examination fee paid 
Examination procedure16.07.2015Examination requested  [2015/44]
08.02.2016Amendment by applicant (claims and/or description)
25.08.2016Despatch of a communication from the examining division (Time limit: M04)
22.12.2016Reply to a communication from the examining division
16.05.2018Despatch of a communication from the examining division (Time limit: M04)
25.09.2018Reply to a communication from the examining division
05.12.2018Despatch of a communication from the examining division (Time limit: M06)
12.04.2019Reply to a communication from the examining division
05.11.2019Despatch of a communication from the examining division (Time limit: M02)
14.01.2020Reply to a communication from the examining division
13.07.2020Despatch of a communication from the examining division (Time limit: M04)
20.11.2020Reply to a communication from the examining division
26.05.2021Communication of intention to grant the patent
29.09.2021Fee for grant paid
29.09.2021Fee for publishing/printing paid
29.09.2021Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  25.08.2016
Opposition(s)11.08.2022No opposition filed within time limit [2022/42]
Fees paidRenewal fee
28.12.2015Renewal fee patent year 03
27.12.2016Renewal fee patent year 04
27.12.2017Renewal fee patent year 05
31.12.2018Renewal fee patent year 06
27.12.2019Renewal fee patent year 07
28.12.2020Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU23.12.2013
AL10.11.2021
AT10.11.2021
CY10.11.2021
CZ10.11.2021
DK10.11.2021
EE10.11.2021
ES10.11.2021
FI10.11.2021
HR10.11.2021
IT10.11.2021
LT10.11.2021
LV10.11.2021
MC10.11.2021
MK10.11.2021
MT10.11.2021
NL10.11.2021
PL10.11.2021
RO10.11.2021
RS10.11.2021
SE10.11.2021
SI10.11.2021
SK10.11.2021
SM10.11.2021
TR10.11.2021
IE23.12.2021
LU23.12.2021
BE31.12.2021
CH31.12.2021
LI31.12.2021
BG10.02.2022
NO10.02.2022
GR11.02.2022
IS10.03.2022
PT10.03.2022
[2026/04]
Former [2024/41]HU23.12.2013
AL10.11.2021
AT10.11.2021
CY10.11.2021
CZ10.11.2021
DK10.11.2021
EE10.11.2021
ES10.11.2021
FI10.11.2021
HR10.11.2021
IT10.11.2021
LT10.11.2021
LV10.11.2021
MC10.11.2021
MK10.11.2021
MT10.11.2021
NL10.11.2021
PL10.11.2021
RO10.11.2021
RS10.11.2021
SE10.11.2021
SI10.11.2021
SK10.11.2021
SM10.11.2021
IE23.12.2021
LU23.12.2021
BE31.12.2021
CH31.12.2021
LI31.12.2021
BG10.02.2022
NO10.02.2022
GR11.02.2022
IS10.03.2022
PT10.03.2022
Former [2024/22]HU23.12.2013
AL10.11.2021
AT10.11.2021
CY10.11.2021
CZ10.11.2021
DK10.11.2021
EE10.11.2021
ES10.11.2021
FI10.11.2021
HR10.11.2021
IT10.11.2021
LT10.11.2021
LV10.11.2021
MC10.11.2021
MK10.11.2021
NL10.11.2021
PL10.11.2021
RO10.11.2021
RS10.11.2021
SE10.11.2021
SI10.11.2021
SK10.11.2021
SM10.11.2021
IE23.12.2021
LU23.12.2021
BE31.12.2021
CH31.12.2021
LI31.12.2021
BG10.02.2022
NO10.02.2022
GR11.02.2022
IS10.03.2022
PT10.03.2022
Former [2023/30]HU23.12.2013
AL10.11.2021
AT10.11.2021
CY10.11.2021
CZ10.11.2021
DK10.11.2021
EE10.11.2021
ES10.11.2021
FI10.11.2021
HR10.11.2021
IT10.11.2021
LT10.11.2021
LV10.11.2021
MC10.11.2021
NL10.11.2021
PL10.11.2021
RO10.11.2021
RS10.11.2021
SE10.11.2021
SI10.11.2021
SK10.11.2021
SM10.11.2021
IE23.12.2021
LU23.12.2021
BE31.12.2021
CH31.12.2021
LI31.12.2021
BG10.02.2022
NO10.02.2022
GR11.02.2022
IS10.03.2022
PT10.03.2022
Former [2023/27]HU23.12.2013
AL10.11.2021
AT10.11.2021
CZ10.11.2021
DK10.11.2021
EE10.11.2021
ES10.11.2021
FI10.11.2021
HR10.11.2021
IT10.11.2021
LT10.11.2021
LV10.11.2021
MC10.11.2021
NL10.11.2021
PL10.11.2021
RO10.11.2021
RS10.11.2021
SE10.11.2021
SI10.11.2021
SK10.11.2021
SM10.11.2021
IE23.12.2021
LU23.12.2021
BE31.12.2021
CH31.12.2021
LI31.12.2021
BG10.02.2022
NO10.02.2022
GR11.02.2022
IS10.03.2022
PT10.03.2022
Former [2023/03]AL10.11.2021
AT10.11.2021
CZ10.11.2021
DK10.11.2021
EE10.11.2021
ES10.11.2021
FI10.11.2021
HR10.11.2021
LT10.11.2021
LV10.11.2021
MC10.11.2021
NL10.11.2021
PL10.11.2021
RO10.11.2021
RS10.11.2021
SE10.11.2021
SI10.11.2021
SK10.11.2021
SM10.11.2021
IE23.12.2021
LU23.12.2021
BE31.12.2021
CH31.12.2021
LI31.12.2021
BG10.02.2022
NO10.02.2022
GR11.02.2022
IS10.03.2022
PT10.03.2022
Former [2023/01]AL10.11.2021
AT10.11.2021
CZ10.11.2021
DK10.11.2021
EE10.11.2021
ES10.11.2021
FI10.11.2021
HR10.11.2021
LT10.11.2021
LV10.11.2021
MC10.11.2021
NL10.11.2021
PL10.11.2021
RO10.11.2021
RS10.11.2021
SE10.11.2021
SI10.11.2021
SK10.11.2021
SM10.11.2021
IE23.12.2021
LU23.12.2021
BE31.12.2021
BG10.02.2022
NO10.02.2022
GR11.02.2022
IS10.03.2022
PT10.03.2022
Former [2022/49]AL10.11.2021
AT10.11.2021
CZ10.11.2021
DK10.11.2021
EE10.11.2021
ES10.11.2021
FI10.11.2021
HR10.11.2021
LT10.11.2021
LV10.11.2021
MC10.11.2021
NL10.11.2021
PL10.11.2021
RO10.11.2021
RS10.11.2021
SE10.11.2021
SK10.11.2021
SM10.11.2021
IE23.12.2021
LU23.12.2021
BG10.02.2022
NO10.02.2022
GR11.02.2022
IS10.03.2022
PT10.03.2022
Former [2022/48]AT10.11.2021
CZ10.11.2021
DK10.11.2021
EE10.11.2021
ES10.11.2021
FI10.11.2021
HR10.11.2021
LT10.11.2021
LV10.11.2021
MC10.11.2021
NL10.11.2021
PL10.11.2021
RO10.11.2021
RS10.11.2021
SE10.11.2021
SK10.11.2021
SM10.11.2021
IE23.12.2021
LU23.12.2021
BG10.02.2022
NO10.02.2022
GR11.02.2022
IS10.03.2022
PT10.03.2022
Former [2022/46]AT10.11.2021
CZ10.11.2021
DK10.11.2021
EE10.11.2021
ES10.11.2021
FI10.11.2021
HR10.11.2021
LT10.11.2021
LV10.11.2021
MC10.11.2021
NL10.11.2021
PL10.11.2021
RO10.11.2021
RS10.11.2021
SE10.11.2021
SK10.11.2021
SM10.11.2021
LU23.12.2021
BG10.02.2022
NO10.02.2022
GR11.02.2022
IS10.03.2022
PT10.03.2022
Former [2022/39]AT10.11.2021
CZ10.11.2021
DK10.11.2021
EE10.11.2021
ES10.11.2021
FI10.11.2021
HR10.11.2021
LT10.11.2021
LV10.11.2021
MC10.11.2021
NL10.11.2021
PL10.11.2021
RO10.11.2021
RS10.11.2021
SE10.11.2021
SK10.11.2021
SM10.11.2021
BG10.02.2022
NO10.02.2022
GR11.02.2022
IS10.03.2022
PT10.03.2022
Former [2022/35]AT10.11.2021
CZ10.11.2021
DK10.11.2021
EE10.11.2021
ES10.11.2021
FI10.11.2021
HR10.11.2021
LT10.11.2021
LV10.11.2021
NL10.11.2021
PL10.11.2021
RO10.11.2021
RS10.11.2021
SE10.11.2021
SK10.11.2021
SM10.11.2021
BG10.02.2022
NO10.02.2022
GR11.02.2022
IS10.03.2022
PT10.03.2022
Former [2022/34]AT10.11.2021
EE10.11.2021
ES10.11.2021
FI10.11.2021
HR10.11.2021
LT10.11.2021
LV10.11.2021
NL10.11.2021
PL10.11.2021
RO10.11.2021
RS10.11.2021
SE10.11.2021
SM10.11.2021
BG10.02.2022
NO10.02.2022
GR11.02.2022
IS10.03.2022
PT10.03.2022
Former [2022/33]AT10.11.2021
ES10.11.2021
FI10.11.2021
HR10.11.2021
LT10.11.2021
LV10.11.2021
NL10.11.2021
PL10.11.2021
RS10.11.2021
SE10.11.2021
SM10.11.2021
BG10.02.2022
NO10.02.2022
GR11.02.2022
IS10.03.2022
PT10.03.2022
Former [2022/25]AT10.11.2021
ES10.11.2021
FI10.11.2021
HR10.11.2021
LT10.11.2021
LV10.11.2021
NL10.11.2021
PL10.11.2021
RS10.11.2021
SE10.11.2021
BG10.02.2022
NO10.02.2022
GR11.02.2022
IS10.03.2022
PT10.03.2022
Former [2022/24]AT10.11.2021
ES10.11.2021
FI10.11.2021
HR10.11.2021
LT10.11.2021
LV10.11.2021
NL10.11.2021
PL10.11.2021
RS10.11.2021
SE10.11.2021
BG10.02.2022
GR11.02.2022
IS10.03.2022
PT10.03.2022
Former [2022/23]AT10.11.2021
ES10.11.2021
FI10.11.2021
HR10.11.2021
LT10.11.2021
LV10.11.2021
PL10.11.2021
RS10.11.2021
BG10.02.2022
PT10.03.2022
Former [2022/22]AT10.11.2021
FI10.11.2021
LT10.11.2021
RS10.11.2021
BG10.02.2022
Former [2022/21]AT10.11.2021
RS10.11.2021
BG10.02.2022
Former [2022/19]BG10.02.2022
Cited inInternational search[XI] WO2011020024  (UNIV JOHNS HOPKINS et al.)
by applicantWO2011020024
 WO9404678
 WO9425591
 US6005079
 US4444887
 US4716111
 WO9846645
 WO9850433
 WO9824893
 WO9816654
 WO9634096
 WO9633735
 WO9110741
 US5916771
 US5413923
 US5625126
 US5633425
 US5569825
 US5661016
 US5545806
 US5814318
 US5939598
 US6311415
 US5807715
 US4816567
 US4816397
 EP0239400
 WO9109967
 US5225539
 US5530101
 US5585089
 EP0592106
 EP0519596
 US5565332
 WO9317105
 US5766886
 US6407213
 US2005037000
 US2005064514
 US7317091
 US7083784
 US7670600
 US8088376
 US2004049014
 US2003229208
 US6350861
 US6180370
 US5693762
 US5693761
 US6331415
 GB2188638
 GB2209757
 WO9201047
 WO9002809
 WO9110737
 WO9218619
 WO9311236
 WO9515982
 WO9520401
 US5698426
 US5223409
 US5403484
 US5580717
 US5427908
 US5750753
 US5821047
 US5571698
 US5516637
 US5780225
 US5658727
 US5733743
 US5969108
 WO9222324
 US4946778
 US5258498
 WO2004029207
 WO2004029092
 WO2004028564
 WO9958572
 WO9951642
 WO9823289
 WO8907142
 WO8807089
 US5843597
 US5642821
 US6194551
 WO0042072
 US6277375
 US4179337
 US6982323
 US4741900
 US4676980
 US6019968
 US598520
 US5934272
 US5874064
 US5855913
 US5290540
 US4880078
 WO9219244
 WO9732572
 WO9744013
 WO9831346
 WO9966903
 US4485045
 US4544545
 US5013556
 US2005074403
 US6787153
 US4526938
 WO9105548
 WO9620698
 US5679377
 US5916597
 US5912015
 US5989463
 US5128326
 WO9915154
 WO9920253
 US5945155
 US5888533
 US4980286
 US5441050
   DONG, C. ET AL.: "Immune Regulation by Novel Costimulatory Molecules", IMMUNOLOG. RES., vol. 28, no. 1, 2003, pages 39 - 48
   VIGLIETTA, V. ET AL.: "Modulating Co- Stimulation", NEUROTHERAPEUTICS, vol. 4, 2007, pages 666 - 675
   KORMAN, A.J. ET AL.: "Checkpoint Blockade in Cancer Immunotherapy", ADV. IMMUNOL., vol. 90, 2007, pages 297 - 339
   WANG, L. ET AL.: "VISTA, A Novel Mouse Ig Superfamily Ligand That Negatively Regulates T Cell Responses", J. EXP. MED., 7 March 2011 (2011-03-07)
   LEPENIES, B. ET AL.: "The Role Of Negative Costimulators During Parasitic Infections", ENDOCRINE, METABOLIC & IMMUNE DISORDERS - DRUG TARGETS, vol. 8, 2008, pages 279 - 288
   SHARPE, A.H. ET AL.: "The B7-CD28 Superfamily", NATURE REV. IMMUNOL., vol. 2, 2002, pages 116 - 126
   LINDLEY, P.S. ET AL.: "The Clinical Utility Of Inhibiting CD28-Mediated Costimulation", IMMUNOL. REV., vol. 229, 2009, pages 307 - 321
   LINDLEY, P.S. ET AL.: "The Clinical Utility Oflnhibiting CD28-Mediated Costimulation", IMMUNOL. REV., vol. 229, 2009, pages 307 - 321
   GREENWALD, R.J. ET AL.: "The B7 Family Revisited", ANN. REV. IMMUNOL., vol. 23, 2005, pages 515 - 548
   GROSS, J. ET AL.: "Identification And Distribution Of The Costimulatory Receptor CD28 In The Mouse", J. IMMUNOL., vol. 149, 1992, pages 380 - 388
   LINSLEY, P. ET AL.: "Intracellular Trafficking Of CTLA4 And Focal Localization Towards Sites Of TCR Engagement", IMMUNITY, vol. 4, 1996, pages 535 - 543
   COYLE, A.J. ET AL.: "The Expanding B7 Superfamily: Increasing Complexity In Costimulatory Signals Regulating T Cell Function", NATURE IMMUNOL., vol. 2, no. 3, 2001, pages 203 - 209
   COLLINS, M. ET AL.: "The B7 Family Of Immune-Regulatory Ligands", GENOME BIOL., vol. 6, 2005, pages 223.1 - 223.7
   LOKE, P. ET AL.: "Emerging Mechanisms Of Immune Regulation: The Extended B7 Family And Regulatory T Cells", ARTHRITIS RES. THER., vol. 6, 2004, pages 208 - 214
   FLIES, D.B. ET AL.: "The New B7s: Playing a Pivotal Role in Tumor Immunity", J. IMMUNOTHER., vol. 30, no. 3, 2007, pages 251 - 260
   AGARWAL, A. ET AL.: "The Role Of Positive Costimulatory Molecules In Transplantation And Tolerance", CURR. OPIN. ORGAN TRANSPLANT, vol. 13, 2008, pages 366 - 372
   LENSCHOW, D.J. ET AL.: "CD28/B7 System of T Cell Costimulation", ANN. REV. IMMUNOL., vol. 14, 1996, pages 233 - 258
   WANG, S. ET AL.: "Co-Signaling Molecules Of The B7-CD28 Family In Positive And Negative Regulation Of T Lymphocyte Responses", MICROBES INFECT., vol. 6, 2004, pages 759 - 766
   SICA, G.L. ET AL.: "B7-4, A Molecule Of The B7 Family, Negatively Regulates T Cell Immunity", IMMUNITY, vol. 18, 2003, pages 849 - 861
   ZANG, X. ET AL.: "B7x: A Widely Expressed B7 Family Member That Inhibits T Cell Activation", PROC. NATL. ACAD. SCI. (USA, vol. 100, 2003, pages 10388 - 10392
   PRASAD, D.V. ET AL.: "B7S1, A Novel B7 Family Member That Negatively Regulates T Cell Activation", IMMUNITY, vol. 18, 2003, pages 863 - 873
   FLAJNIK, M.F. ET AL.: "Evolution Of The B7 Family: Co-Evolution Of B7H6 And Nkp30, Identification Of A New B7 Family Member, B7H7, And Of B7's Historical Relationship With The MHC", IMMUNOGENETICS, vol. 64, 2012, pages 571 - 590
   KEIR, M.E. ET AL.: "PD-1 And Its Ligands In Tolerance And Immunity", ANNU. REV. IMMUNOL., vol. 26, 2008, pages 677 - 704
   ZOU, W. ET AL.: "Inhibitory B7-Family Molecules In The Tumour Microenvironment", NAT. REV. IMMUNOL., vol. 8, 2008, pages 467 - 477
   FLAJNIK, M.F. ET AL.: "Evolution Of The B7 Family: Co-Evolution OfB7H6 And Nkp30, Identification OfA New B7 Family Member, B 7H7, And Of B7's Historical Relationship With The MHC", IMMUNOGENETICS, vol. 64, 2012, pages 571 - 590
   YHU ET AL., NATURE COMMUNICATIONS, vol. 4, 2013, pages 1 - 12
   MAGER, D.L. ET AL.: "Endogenous Retroviruses Provide The Primary Polyadenylation Signal For Two New Human Genes (HHLA2 And HHLA3", GENOMICS, vol. 59, 1999, pages 255 - 263
   FLAJNIK, M.F. ET AL.: "Evolution Of The B7 Family: Co-Evolution Of B7H6 And Nkp30, Identification OfA New B7 Family Member, B7H7, And OfB7's Historical Relationship With The MHC", IMMUNOGENETICS, vol. 64, 2012, pages 571 - 590
   RAHIMI, N. ET AL.: "Identification Of IGPR-1 As A Novel Adhesion Molecule Involved In Angiogenesis", MOLEC. BIOL. CELL, vol. 23, no. 9, 14 March 2012 (2012-03-14), pages 1646 - 1656
   KABAT: "Sequences ofProteins oflmmunological Interest", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH
   CHOTHIA; LESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
   MUYLDERMANS ET AL., TRENDS BIOCHEM. SCI., vol. 26, 2001, pages 230
   NUTTALL ET AL., CUR. PHARM. BIOTECH., vol. 1, 2000, pages 253
   REICHMANN; MUYLDERMANS, J. IMMUNOL. METH., vol. 231, 1999, pages 25
   PLUCKTHUN: "The Pharmacology ofmonoclonal Antibodies", vol. 113, 1994, SPRINGER-VERLAG, pages: 269 - 315
   LONBERG; HUSZAR, INT. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93
   MORRISON, SCIENCE, vol. 229, 1985, pages 1202
   OI ET AL., BIOTECHNIQUES, vol. 4, 1986, pages 214
   GILLIES ET AL., J. IMMUNOL. METHODS, vol. 125, 1989, pages 191 - 202
   PADLAN, MOLECULAR IMMUNOLOGY, vol. 28, no. 4/5, 1991, pages 489 - 498
   STUDNICKA, PROTEIN ENGINEERING, vol. 7, 1994, pages 805
   ROGUSKA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 969
   STUDNICKA ET AL., PROTEIN ENGINEERING, vol. 7, no. 6, 1994, pages 805 - 814
   ROGUSKA ET AL., PNAS, vol. 91, 1994, pages 969 - 973
   TAN ET AL., IMMUNOL., vol. 169, 2002, pages 1119 - 1125
   CALDAS ET AL., PROTEIN ENG., vol. 13, 2000, pages 353 - 360
   MOREA ET AL., METHODS, vol. 20, 2000, pages 267 - 79
   BACA ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 10678 - 10684
   ROGUSKA, PROTEIN ENG., vol. 9, 1996, pages 895 - 904
   COUTO ET AL., CANCER RES., vol. 55, no. 23, 1995, pages 5973S - 5977S
   COUTO ET AL., CANCER RES., vol. 55, 1995, pages 1717 - 22
   SANDHU, GENE, vol. 150, 1994, pages 409 - 10
   PEDERSEN ET AL., J. MOL. BIOL., vol. 235, 1994, pages 959 - 973
   JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
   REICHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329
   PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596
   CHOTHIA ET AL.: "Structural Determinants In The Sequences Of Immunoglobulin Variable Domain", J. MOL. BIOL., vol. 278, 1998, pages 457 - 479
   ROGUSKA ET AL., PROC. NATL. ACAD. SCI., vol. 91, 1994, pages 969 - 973
   TAN ET AL., J IMMUNOL., vol. 169, 2002, pages 1119 - 25
   CALDAS ET AL., PROTEIN ENG., vol. 13, 2000, pages 353 - 60
   BACA ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 10678 - 84
   ROGUSKA ET AL., PROTEIN ENG., vol. 9, 1996, pages 895 - 904
   COUTO, CANCER RES., vol. 55, no. 23, 1995, pages 5973S - 5977S
   PEDERSEN ET AL., J. MOL. BIOL., vol. 235, 1994, pages 959 - 73
   RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323
   GOEDDEL: "Gene Expression Technology Methods in Enzymology", vol. 185, 1991, ACADEMIC PRESS
   BORREBACK: "Antibody Engineering", 1992, W. H. FREEMAN
   MAYFORTH: "Designing Antibodies", 1993, ACADEMIC PRESS
   GREENSPAN, N.S. ET AL.: "Idiotypes: Structure And Immunogenicity", FASEB J., vol. 7, 1989, pages 437 - 444
   NISINOFF, A.: "Idiotypes: Concepts And Applications", J. IMMUNOL., vol. 147, no. 8, 1991, pages 2429 - 2438
   BRINKMAN, U. ET AL.: "Phage Display Of Disulfide-Stabilized Fv Fragments", J. IMMUNOL. METHODS, vol. 182, 1995, pages 41 - 50
   AMES, R.S. ET AL.: "Conversion OfMurine Fabs Isolated From A Combinatorial Phage Display Library To Full Length Immunoglobulins", J. IMMUNOL. METHODS, vol. 184, 1995, pages 177 - 186
   KETTLEBOROUGH, C.A. ET AL.: "Isolation Of Tumor Cell-Specific Single-Chain Fv From Immunized Mice Using Phage-Antibody Libraries And The Re-Construction Of Whole Antibodies From These Antibody Fragments", EUR. J. IMMUNOL., vol. 24, 1994, pages 952 - 958
   PERSIC, L. ET AL.: "An Integrated Vector System For The Eukaryotic Expression OfAntibodies Or Their Fragments After Selection From Phage Display Libraries", GENE, vol. 187, 1997, pages 9 - 18
   BURTON, D.R. ET AL.: "Human Antibodies From Combinatorial Libraries", ADV. IMMUNOL., vol. 57, 1994, pages 191 - 280
   MULLINAX, R.L. ET AL.: "Expression OfA Heterodimeric Fab Antibody Protein In One Cloning Step", BIOTECHNIQUES, vol. 12, no. 6, 1992, pages 864 - 869
   SAWAI ET AL.: "Direct Production Of The Fab Fragment Derived From The Sperm Immobilizing Antibody Using Polymerase Chain Reaction And cDNA Expression Vectors", AM. J. REPROD. IMMUNOL., vol. 34, 1995, pages 26 - 34
   BETTER, M. ET AL.: "Escherichia coli Secretion OfAn Active Chimeric Antibody Fragment", SCIENCE, vol. 240, 1988, pages 1041 - 1043
   HUSTON, J.S. ET AL.: "Protein Engineering OfSingle- Chain Fv Analogs And Fusion Proteins", METHODS IN ENZYMOLOGY, vol. 203, 1991, pages 46 - 88
   SHU, L. ET AL.: "Secretion OfA Single-Gene-Encoded Immunoglobulin From Myeloma Cells", PROC. NATL. ACAD. SCI. (USA, vol. 90, pages 7995 - 7999
   SKERRA. A. ET AL.: "Assembly OfA Functional Immunoglobulin Fv Fragment In Escherichia coli", SCIENCE, vol. 240, 1988, pages 1038 - 1040
   GLASER, S.M. ET AL.: "Antibody Engineering By Codon-Based Mutagenesis In A Filamentous Phage Vector System", J. IMMUNOL., vol. 149, 1992, pages 3903 - 3913
   WU, H. ET AL.: "Stepwise In Vitro Affinity Maturation Of Vitaxin, An Alphav Beta3-Specific Humanized Mab", PROC. NATL. ACAD. SCI. (USA, vol. 95, no. 11, 1998, pages 6037 - 6042
   YELTON, D.E. ET AL.: "Affinity Maturation Of The BR96 Anti-Carcinoma Antibody By Codon-Based Mutagenesis", J. IMMUNOL., vol. 155, 1995, pages 1994 - 2004
   SCHIER ET AL.: "Isolation Of Picomolar Affinity Anti-C-Erbb-2 Single-Chain Fv By Molecular Evolution Of The Complementarity Determining Regions In The Center Of The Antibody Binding Site", J. MOL. BIOL., vol. 263, 1996, pages 551 - 567
   WU, H. ET AL.: "Stepwise In Vitro Affinity __ Maturation Of Vitaxin, An Alphav Beta3-Specific Humanized Mab", PROC. NATL. ACAD. SCI. - (USA, vol. 95, no. 11, 1998, pages 6037 - 6042
   KRAUSE, J.C. ET AL.: "An Insertion Mutation That Distorts Antibody Binding Site Architecture Enhances Function OfA Human Antibody", MBIO., vol. 2, no. 1, 2011, pages E00345 - 10
   KUAN, C.T. ET AL.: "Affinity-Matured Anti-Glycoprotein NMB Recombinant Immunotoxins Targeting Malignant Gliomas And Melanomas", INT. J. CANCER, 2010
   HACKEL, B.J. ET AL.: "Stability And CDR Composition Biases Enrich Binder Functionality Landscapes", J. MOL. BIOL., vol. 401, no. 1, 2010, pages 84 - 96
   MONTGOMERY, D.L. ET AL.: "Affinity Maturation And Characterization OfA Human Monoclonal Antibody Against HIV-1 gp41", MABS, vol. 1, no. 5, 2009, pages 462 - 474
   GUSTCHINA, E. ET AL.: "Affinity Maturation By Targeted Diversification Of The CDR-H2 Loop OfA Monoclonal Fab Derived From A Synthetic Nave Human Antibody Library And Directed Against The Internal Trimeric Coiled-Coil Of Gp41 Yields A Set Of Fabs With Improved HIV-1 Neutralization Potency And Breadth", VIROLOGY, vol. 393, no. 1, 2009, pages 112 - 119
   FINLAY, W.J. ET AL.: "Affinity Maturation Of A Humanized Rat Antibody For Anti-RAGE Therapy: Comprehensive Mutagenesis Reveals A High Level Of Mutational Plasticity Both Inside And Outside The Complementarity-Determining Regions", J. MOL. BIOL., vol. 388, no. 3, 2009, pages 541 - 558
   BOSTROM, J. ET AL.: "Improving Antibody Binding Affinity And Specificity For Therapeutic Development", METHODS MOL. BIOL., vol. 525, 2009, pages 353 - 376
   STEIDL, S. ET AL.: "In Vitro Affinity Maturation Of Human GM-CSF Antibodies By Targeted CDR-Diversification", MOL. IMMUNOL., vol. 46, no. 1, 2008, pages 135 - 144
   BARDERAS, R. ET AL.: "Affinity maturation of antibodies assisted by in silico modeling", PROC. NATL. ACAD. SCI. (USA, vol. 105, no. 26, 2008, pages 9029 - 9034
   SHIELDS, R.L. ET AL.: "Lack Of Fucose On Human IgG N-Linked Oligosaccharide Improves Binding To Human Fcgamma RIII And Antibody-Dependent Cellular Toxicilv.", J. BIOL. CHEM., vol. 277, no. 30, 2002, pages 26733 - 26740
   DAVIES J. ET AL.: "Expression OfGnTIII In A Recombinant Anti-CD20 CHO Production Cell Line: Expression Of Antibodies With Altered Glycoforms Leads To An Increase In ADCC Through Higher Affinity For FC Gamma RIII", BIOTECHNOLOGY & BIOENGINEERING, vol. 74, no. 4, 2001, pages 288 - 294
   WALLICK, S.C. ET AL.: "Glycosylation OfA VH Residue OfA Monoclonal Antibody Against Alpha (1----6) Dextran Increases Its Affinity For Antigen", J. EXP. MED., vol. 168, no. 3, 1988, pages 1099 - 1109
   TAO, M.H. ET AL.: "Studies OfAglycosylated Chimeric Mouse-Human IgG. Role Of Carbohydrate In The Structure And Effector Functions Mediated By The Human IgG Constant Region", J. IMMUNOL., vol. 143, no. 8, 1989, pages 2595 - 2601
   ROUTLEDGE, E.G. ET AL.: "The Effect OfAglycosylation On The Immunogenicity Of A Humanized Therapeutic CD3 Monoclonal Antibody", TRANSPLANTATION, vol. 60, no. 8, 1995, pages 847 - 53
   ELLIOTT, S. ET AL.: "Enhancement Of Therapeutic Protein In Vivo Activities Through Glycoengineering", NATURE BIOTECHNOL., vol. 21, 2003, pages 414 - 21
   SHIELDS, R.L. ET AL.: "Lack Of Fucose On Human IgG N-Linked Oligosaccharide Improves Binding To Human Fcgamma RIll And Antibody-Dependent Cellular Toxicity", J. BIOL. CHEM., vol. 277, no. 30, 2002, pages 26733 - 26740
   RIECHMANN, L. ET AL.: "Reshaping Human Antibodies For Therapy", NATURE, vol. 332, 1988, pages 323 - 327
   ARNON ET AL.: "MONOCLONAL ANTIBODIES AND CANCER THERAPY", 1985, ALAN R. LISS, INC., article "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", pages: 243 - 56
   HELLSTROM ET AL.: "CONTROLLED DRUG DELIVERY", 1987, MARCEL DEKKER, INC., article "Antibodies For Drug Delivery", pages: 623 - 53
   THORPE ET AL.: "MONOCLONAL ANTIBODIES '84: BIOLOGICAL AND CLINICAL APPLICATIONS", 1985, article "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", pages: 475 - 506
   "MONOCLONAL ANTIBODIES FOR CANCER DETECTION AND THERAPY", 1985, ACADEMIC PRESS, article "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", pages: 303 - 16
   THORPE ET AL.: "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", IMMUNOL. REV., vol. 62, 1982, pages 119 - 158
   MUELLER, J.P. ET AL.: "Humanized Porcine VCAM-Specific Monoclonal Antibodies With Chimeric IgG2/G4 Constant Regions Block Human Leukocyte Binding To Porcine Endothelial Cells", MOL. IMMUN., vol. 34, no. 6, 1997, pages 441 - 452
   SWANN, P.G.: "Considerations For The Development Of Therapeutic Monoclonal Antibodies", CURR. OPIN. IMMUN., vol. 20, 2008, pages 493 - 499
   PRESTA, L.G.: "Molecular Engineering And Design Of Therapeutic Antibodies", CURR. OPIN. IMMUN., vol. 20, 2008, pages 460 - 470
   ANGAL, S. ET AL.: "A Single Amino Acid Substitution Abolishes The Heterogeneity Of Chimeric Mouse/Human (Igg4) Antibody", MOLEC. IMMUNOL., vol. 30, no. 1, 1993, pages 105 - 108
   MUELLER, J.P. ET AL.: "Humanized Porcine VCAM-Specific Monoclonal Antibodies With Chimeric Igg2/G4 Constant Regions Block Human Leukocyte Binding To Porcine Endothelial Cells", MOL. IMMUN., vol. 34, no. 6, 1997, pages 441 - 452
   STAVENHAGEN, J.B. ET AL.: "Fc Optimization Of Therapeutic Antibodies Enhances Their Ability To Kill Tumor Cells In Vitro And Controls Tumor Expansion In Vivo Via Low-Affinity Activating Fcgamma Receptors", CANCER RES., vol. 57, no. 18, 2007, pages 8882 - 8890
   WILSON, LA. ET AL.: "The Structure OfAn Antigenic Determinant In A Protein", CELL, vol. 37, 1984, pages 767 - 778
   KNAPPIK, A. ET AL.: "An Improved Affinity Tag Based On The FLAG Peptide For The Detection And Purification Of Recombinant Antibody Fragments", BIOTECHNIQUES, vol. 17, no. 4, 1994, pages 754 - 761
   "Physician's Desk Reference", 2002
   CARTER, C. A. ET AL.: "Cell Biology OfHIV-1 Infection Of Macro phages", ANN. REV. MICROBIOL., vol. 62, 2008, pages 425 - 443
   NOURSADEGHI, M. ET AL.: "HIV Infection Of Mononuclear Phagocytic Cells: The Case For Bacterial Innate Immune Deficiency In AIDS", LANCET INFECT. DIS., vol. 6, 2006, pages 794 - 804
   FISHMAN: "Medicine", 1985, J.B. LIPPINCOTT CO.
   MURPHY ET AL.: "Informed Decisions: The Complete Book of Cancer Diagnosis, Treatment, and Recovery", 1997, VIKING PENGUIN, PENGUIN BOOKS U.S.A., INC.
   WALLMANN, J. ET AL.: "Anti-Ids in Allergy: Timeliness of a Classic Concept", WORLD ALLERGY ORGANIZ. J., vol. 3, no. 6, 2010, pages 195 - 201
   NARDI, M. ET AL.: "Antiidiotype Antibody Against Platelet Anti-Gpllla Contributes To .The Regulation Of Thrombocytopenia In HIV-1-ITP Patients", J. EXP. MED., vol. 191, no. 12, 2000, pages 2093 - 2100
   ZANG, 'Y.C. ET AL.: "Human Anti-Idiotypic T Cells Induced By TCR Peptides Corresponding To A Common CDR3 Sequence Motif In Myelin Basic Protein-Reactive T Cells", INT. IMMUNOL., vol. 15, no. 9, 2003, pages 1073 - 1080
   LOIARRO, M. ET AL.: "Targeting TLRlIL-1R Signalling In Human Diseases", MEDIATORS INFLAMM., 8 April 2010 (2010-04-08), pages 674363
   WU; WU, J BIOL. CHEM., vol. 262, 1987, pages 4429 - 4432
   EPSTEIN, PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 3688
   HWANG, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4030 - 4
   BENDAS ET AL., BIODRUGS, vol. 15, no. 4, 2001, pages 215 - 224
   ALLEN ET AL., FEBS LETT., vol. 223, 1987, pages 42 - 6
   KLIBANOV ET AL., FEBS LETT., vol. 268, 1990, pages 235 - 7
   BLUM, BIOCHIM. BIOPHYS. ACTA., vol. 1029, 1990, pages 91 - 7
   TORCHILIN ET AL., J. LIPOSOME RES., vol. 6, 1996, pages 99 - 116
   LITZINGER ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1190, 1994, pages 99 - 107
   MARUYAMA ET AL., CHEM. PHARM. BULL., vol. 39, 1991, pages 1620 - 2
   KLIBANOV ET AL., BIOCHIM BIOPHYS ACTA, vol. 1062, 1991, pages 142 - 8
   ALLEN ET AL., ADV. DRUG DELIV. REV, vol. 13, 1994, pages 285 - 309
   MARTIN ET AL., J. BIOL. CHEM., vol. 257, 1982, pages 286 - 288
   ALLEN ET AL.: "Stealth Liposomes", 1995, CRC PRESS, pages: 233 - 44
   HANSEN ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1239, 1995, pages 133 - 144
   NING ET AL.: "Intratumoral Radioimmunotheraphy of a Human Colon Cancer Xenograft Using a Sustained-Release Gel", RADIOTHERAPY & ONCOLOGY, vol. 39, 1996, pages 179 - 189
   SONG ET AL.: "Antibody Mediated Lung Targeting of Long-Circulating Emulsions", PDA JOURNAL OF PHARMACEUTICAL SCIENCE & TECHNOLOGY, vol. 50, 1995, pages 3 72 - 397
   CLEEK ET AL.: "Biodegradable Polymeric Carriers for a bFGF Antibody for Cardiovascular Application", PRO. INT'L. SYMP. CONTROL. REL. BIOACT. MATER., vol. 24, 1997, pages 853 - 854
   LAM ET AL.: "Microencapsulation of Recombinant Humanized Monoclonal Antibody for Local Delivery", PROC. INT'L. SYMP. CONTROL REL. BIOACT. MATER., vol. 24, 1997, pages 759 - 760
   SEFTON, CRC CRIT. REF BIOMED. ENG., vol. 14, 1987, pages 20
   BUCHWALD ET AL., SURGERY, vol. 88, 1980, pages 507
   SAUDEK ET AL., N. ENGL. ,/ MED., vol. 321, 1989, pages 574
   "Medical Applications of Controlled Release", 1974, CRC PRES.
   "Controlled Drug Bioavailability, Drug Product Design and Performance", 1984, WILEY
   RANGER; PEPPAS, J., MACROMOL. SCI. REV. MACROMOL. CHEM., vol. 23, 1983, pages 61
   LEVY ET AL., SCIENCE, vol. 228, 1985, pages 190
   DURING ET AL., ANN. NEUROL., vol. 25, 1989, pages 351
   HOWARD ET AL., J. NEUROSURG., vol. 7 1, 1989, pages 105
   GOODSON, MEDICAL APPLICATIONS OF CONTROLLED RELEASE, vol. 2, 1984, pages 115 - 138
   LANGER, SCIENCE, vol. 249, 1990, pages 1527 - 1533
   NING ET AL., RADIOTHERAPY & ONCOLOGY, vol. 39, 1996, pages 179 - 189
   SONG ET AL., PDA JOURNAL OF PHARMACEUTICAL SCIENCE & TECHNOLOGY, vol. 50, 1995, pages 372 - 397
   CLEEK, PRO. INT'L. SYMP. CONTROL. REL. BIOACT. MATER., vol. 24, 1997, pages 853 - 854
   LAM ET AL., PROC. INT'L. SYMP. CONTROL REL. BIOACT. MATER., vol. 24, 1997, pages 759 - 760
   JOLIOT ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 1864 - 1868
   S.W. BURCHIEL ET AL.: "TUMOR IMAGING: THE RADIOCHEMICAL DETECTION OF CANCER", 1982, MASSON PUBLISHING INC., article "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments"
   SALI, A. ET AL.: "Comparative Protein Modelling By Satisfaction Of Spatial Restraints", J. MOLEC. BIOL., vol. 234, no. 3, 1993, pages 779 - 815
   CHOTHIA, C. ET AL.: "Canonical Structures For The Hypervariable Regions Oflmmunoglobulins", J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
   MARTIN, A.C. ET AL.: "Structural Families In Loops Of Homologous Proteins: Automatic Classification, Modelling And Application To Antibodies", J. MOLEC. BIOL., vol. 263, no. 5, 1996, pages 800 - 815
   RUIZ, M. ET AL.: "IMGT Gene Identification And Colliers de Perles Of Human Immunoglobulins With Known 3D Structures", IMMUNOGENETICS, vol. 53, no. 10-11, 2002, pages 857 - 883
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.